{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=18", "query": { "condition": "Advanced Stage Solid Tumors", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 3078, "total_pages": 308, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T13:52:48.202Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02134197", "title": "Dose-escalation Study of Lupartumab Amadotin (BAY1129980)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Lupartumab Amadotin (BAY1129980)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2014-05-22", "completion_date": "2018-08-30", "has_results": false, "last_update_posted_date": "2019-12-11", "last_synced_at": "2026-11-15T13:52:48.202Z", "location_count": 15, "location_summary": "La Jolla, California • Stanford, California • Aurora, Colorado + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02134197" }, { "nct_id": "NCT05103358", "title": "Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tumor", "Tumor, Solid", "Metastasis", "Metastatic Cancer", "Cancer", "Cancer Metastatic", "Tumors", "Neoplasms", "Neoplasm Metastasis", "Solid Tumor", "Advanced Solid Tumor", "Advanced Cancer", "Malignant Solid Tumor", "Malignant Solid Neoplasm", "Malignant Neoplasm", "Malignant Tumor", "TSC", "TSC1", "TSC2", "Metastatic Solid Tumor", "Metastatic Neoplasm" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 128, "start_date": "2022-03-10", "completion_date": "2024-12-23", "has_results": true, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-11-15T13:52:48.202Z", "location_count": 159, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Prescott Valley", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05103358" }, { "nct_id": "NCT01706835", "title": "Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "aldoxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-10", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2022-02-10", "last_synced_at": "2026-11-15T13:52:48.202Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01706835" }, { "nct_id": "NCT00024310", "title": "Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "folic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "lometrexol", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-17", "last_synced_at": "2026-11-15T13:52:48.202Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024310" }, { "nct_id": "NCT00728468", "title": "A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Tumors" ], "interventions": [ { "name": "PF-00299804", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2008-09", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2017-08-02", "last_synced_at": "2026-11-15T13:52:48.202Z", "location_count": 2, "location_summary": "Buffalo, New York • San Antonio, Texas", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00728468" }, { "nct_id": "NCT05662397", "title": "A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Relapsed Cancer", "Refractory Cancer" ], "interventions": [ { "name": "HST-1011", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "HotSpot Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2023-03-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-11-15T13:52:48.202Z", "location_count": 8, "location_summary": "Sarasota, Florida • Las Vegas, Nevada • New York, New York + 5 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05662397" }, { "nct_id": "NCT00020124", "title": "Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Malignant Mesothelioma", "Metastatic Cancer" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-06", "completion_date": "2002-12", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-11-15T13:52:48.202Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020124" }, { "nct_id": "NCT06264921", "title": "A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Solid Tumor, Adult", "Advanced Solid Tumor", "Metastatic Tumor", "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Metastatic Ovarian Carcinoma", "Endometrial Cancer", "Endometrial Neoplasms", "Endometrial Diseases", "Metastatic Endometrial Cancer", "Metastatic Endometrial Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Ovarian Carcinoma", "Gastric Cancer", "Advanced Gastric Carcinoma", "Metastatic Gastric Cancer", "Metastatic Gastric Carcinoma", "Small-cell Lung Cancer", "Small Cell Lung Carcinoma", "Triple Negative Breast Cancer", "Triple Negative Breast Neoplasms", "Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Carcinoma", "CCNE1 Amplification", "Hormone Receptor Negative Breast Carcinoma", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Progesterone-receptor-positive Breast Cancer" ], "interventions": [ { "name": "NKT3447", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NiKang Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2024-02-23", "completion_date": "2025-04-16", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-11-15T13:52:48.202Z", "location_count": 8, "location_summary": "San Francisco, California • Denver, Colorado • Celebration, Florida + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Celebration", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06264921" }, { "nct_id": "NCT03905148", "title": "Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "Lifirafenib", "type": "DRUG" }, { "name": "mirdametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2019-05-01", "completion_date": "2025-10-23", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-11-15T13:52:48.202Z", "location_count": 2, "location_summary": "Santa Monica, California • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03905148" }, { "nct_id": "NCT05838768", "title": "Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers" ], "interventions": [ { "name": "HRO761", "type": "DRUG" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 123, "start_date": "2023-06-27", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-11-15T13:52:48.202Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05838768" } ] }